Metallothionein (MT) is a family of cysteine-rich proteins localized in the membrane of the Golgi apparatus (an organelle in eukaryotic cells). MT can bind with most physiological and xenobiotic heavy metals and MT plays a role in protecting against metal toxicity and oxidative stress. MT also plays a part in transcription factor regulation, and so defects in MT function may lead to malignant transformation of cells and ultimately cancer. Metallothionein also has a part in controlling oxidative stress, metal storage, transportation, binding, and detoxification.
The Wiki page, Apoe4 offers a collection of resources and information that can help you prevent and address health problems related to APOE -ε4 allele. APOE, short for Apolipoprotein E, is both a protein and a gene. As a protein, ApoE is involved in the metabolism of fats (lipids) in the body and comes in different isoforms. In our modern environment, the ε4 allele of the gene confers a higher risk for Alzheimer’s disease and other medical conditions. It is possible to be tested to see if you carry the E4 gene which would mean you are more likely to develop Alzheimer’s, although many other factors also determine vulnerability to Alzheimer’s. E4 is also associated with other chronic diseases including dementia, brain disorders, high cholesterol, infectious diseases susceptibility, gallstones, and cardiovascular disease.
A review published in the Current Neuropharmacology journal in 2018 looked at the impact of dietary fats on brain function. It also examined gut-brain communication through microbiota; the impact of probiotics and prebiotics on brain functions; SCFA’s, microbiota, and neuroinflammation. It reviewed lipid sensing, satiety, and processing of hedonic food; the impact of diet on the hypo-thalamic control of reproduction; neuroprotective effects of N-3 PUFAs; dietary PUFAs, brain PUFAs and the role of PUFAs. The results of this review revealed that dietary fats are both friends and foes for brain functions. However, dietary manipulation for the treatment of brain disorders is not just a promise for the future, but a reality. In fact, the clinical relevance of the manipulation of dietary lipids, as for KDs, is well-known and currently in use for the treatment of brain diseases.
A review by Caldwell B. Esselstyn published in the Journal of Geriatric Cardiology in 2017 covered the connection between a plant-based diet and coronary artery disease. Caldwell states that in ignoring diet as a cause of CVD there is no hope for a cure as patients continue to consume the foods that destroy them. He discusses studies conducted using WFPBN in patients ill with CAD. The results showed that WFPBN can halt and reverse CVD. In summary, current palliative cardiovascular medicine consisting of drugs, stents, and bypass surgery cannot cure or halt the vascular disease epidemic and is financially unsustainable. WFPB can restore the ability of endothelial cells to produce nitric oxide, which can halt and reverse disease without morbidity, mortality, or added expense.
Xylitol is a chemical compound and can be classified as a polyalcohol and sugar alcohol, specifically alditol. Xylitol is used as a food additive, often replacing sugar in foods. It occurs in several fruits and humans and animals naturally make trace amounts during the metabolism of carbohydrates. Xylitol is also produced commercially by fermentation of discarded biomass. Xylitol is water-soluble and like most sugar alcohols, xylitol is achiral. Xylitol has negligible effects on blood sugar because it is metabolized independently of insulin. There are no serious health risks for normal consumption. Increased xylitol consumption can increase oxalate, calcium, and phosphate excretion in urine. About 50% of eaten xylitol is not absorbed by the intestines in humans. Instead, 50–75% of this amount is fermented by gut bacteria to short-chain organic acids and gases. The liver metabolizes 50% of absorbed xylitol. The main metabolic route in humans is: in cytoplasm, nonspecific NAD-dependent dehydrogenase (polyol dehydrogenase) transforms xylitol to D-xylulose. Specific xylulokinase phosphorylates it to D-xylulose-5-phosphate. This then goes to pentose phosphate pathway for further processing.
Farmacy offers a 10-day reset program by Dr. Mark Hyman. The system-based approach is designed to get you back on track and reclaim your health. If you’re feeling sluggish, off your game, run-down or scatterbrained then you need a systematized approach, not a quick fix. You may be feeling this way because of too much sugar, not enough nutritious food, eating late and at the “wrong” time or not getting quality sleep. The restart program focuses on food; supplements and habits. It kicks off with a detox and continued with a set meal plan (ingredients and recipes) plus health supplements. The idea is to break old habits and make new, healthier ones. You are guided through the reset program by a wellness coach, with personal phone support. Ultimately on completing the program you should have healthy blood sugar levels and no longer be dependent on processed carbs and sugar for energy.
Resveratrol – 1g/daily – mornings with yogurt (see where to buy)
Nicotinamide Mononucleotide (NMN) – 1g/daily – mornings (see where to buy)
Metformin (prescription drug) – 1g/daily in the evenings – except on days when exercising
Multivitamins? Only vitamin D3 with K2, he aims to get the rest from his diet
Statin (prescription drug) – taken since his early 20s due to family history of cardiovascular disease
Aspirin – 83mg daily
in normal physiology, glutamine plays a key role in signalling in enterocytes that are part of the intestinal barrier, but it is not clear if supplementing the diet with glutamine is helpful in conditions where there is increased intestinal permeability.
Prebiotics and certain probiotics such as Escherichia coli Nissle 1917 have been found to reduce increased intestinal permeability. Lactobacillus rhamnosus, Lactobacillus reuteri, and Faecalibacterium prausnitzii have also been shown to significantly reduce increased intestinal permeability.
Larazotide acetate (previously known as AT-1001) is a zonulin receptor antagonist that has been probed in clinical trials. It seems to be a drug candidate for use in conjunction with a gluten-free diet in people with celiac disease, with the aim to reduce the intestinal permeability caused by gluten and its passage through the epithelium, and therefore mitigating the resulting cascade of immune reactions. read more>>
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.